SCHEMBL21883580

SCHEMBL21883580

CCc1c(O)c(Cl)cc(F)c1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.41
HSD17B10 Q99714 6/20 0.41
HIF1A Q16665 5/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
CASP7 P55210 3/20 0.41
TSHR P16473 3/20 0.41
CYP1A2 P05177 2/20 0.41
ALOX15 P16050 2/20 0.41
ALOX12 P18054 2/20 0.41
CYP2C19 P33261 2/20 0.41
HTT P42858 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP3A4 P08684 2/20 0.41
RECQL P46063 2/20 0.41
POLB P06746 2/20 0.41
THRB P10828 2/20 0.41
MAPK1 P28482 2/20 0.41
ESR1 P03372 2/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24971842 0.86 HPGD (0.47) HPGDHSD17B10HIF1ASMN1; SMN2CASP7
SCHEMBL23492884 0.81 ESR1 (0.33) HTTMEN1KMT2ARECQLPOLB
SCHEMBL19116110 0.73 GAA (0.36) HPGDHSD17B10HIF1ASMN1; SMN2CASP7
SCHEMBL1548068 0.73 CA1 (0.33) ESR1
SCHEMBL18691189 0.72 HPGD (0.50) HPGDHSD17B10HIF1ASMN1; SMN2CASP7
SCHEMBL20621268 0.72 HSD17B10 (0.41) HPGDHSD17B10HIF1ASMN1; SMN2CASP7
SCHEMBL8726286 0.72 ADRA2A (0.36) HSD17B10HTTMEN1KMT2ACYP3A4
SCHEMBL21883544 0.72 TRPV4 (0.36) ESR1ARESR2TTR
SCHEMBL24870543 0.69 KDM4E (0.33) HPGDHSD17B10HIF1ASMN1; SMN2CASP7
SCHEMBL20254645 0.69 MEN1 (0.40) HPGDSMN1; SMN2TSHRCYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597377-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10597377-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 HPGD 1517/4885HSD17B10 3787/4885HIF1A 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.